Search for: "Boehringer Ingelheim Pharmaceutical, Inc" Results 1 - 20 of 90
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
5 Apr 2020, 9:57 pm by Patent Docs
By Donald Zuhn –- Last month, in Boehringer Ingelheim Pharmaceuticals Inc. v. [read post]
30 Jan 2020, 5:29 am by Brenda Fulmer
The Zantac litigation effort involves several international drug companies, including Boehringer Ingelheim Pharmaceuticals (based in Connecticut); Boehringer Ingelheim Corporation (German parent company); Sanofi US Services, Inc. [read post]
30 Jan 2020, 5:29 am by Brenda Fulmer
The Zantac litigation effort involves several international drug companies, including Boehringer Ingelheim Pharmaceuticals (based in Connecticut); Boehringer Ingelheim Corporation (German parent company); Sanofi US Services, Inc. [read post]
1 Aug 2019, 8:30 am by Seeger Weiss LLP
Boehringer Ingelheim Corp., et al., a $150 million settlement with GlaxoSmithKline PLC, and a $190 million settlement with Aventis Pharmaceuticals, Inc. [read post]
4 Sep 2018, 7:00 am by Todd Presnell
Boehringer Ingelheim Pharmaceuticals, Inc., 892 F.3d 1264 (D.C. [read post]
4 Sep 2018, 7:00 am by Todd Presnell
Boehringer Ingelheim Pharmaceuticals, Inc., 892 F.3d 1264 (D.C. [read post]
9 Jul 2018, 6:30 pm by Todd Presnell
Boehringer Ingelheim Pharmaceuticals, Inc., 2018 WL 3028972 (CADC June 19, 2018). [read post]
9 Jul 2018, 6:30 pm by Todd Presnell
Boehringer Ingelheim Pharmaceuticals, Inc., 2018 WL 3028972 (CADC June 19, 2018). [read post]
11 Jan 2018, 12:30 pm by Tom Lamb
Boehringer Ingelheim Pharmaceuticals, Inc. is the drug company responsible for OFEV in the US. [read post]
1 Jan 2018, 9:46 am
AUSTIN – Texas Attorney General Ken Paxton, along with attorneys general from all other states and the District of Columbia, have reached a $13.5 million settlement with Boehringer Ingelheim Pharmaceuticals Inc. in a complaint over alleged off-label marketing and deceptive claims about four of its prescription drugs. [read post]
29 Nov 2017, 3:29 am
In re Boehringer Ingelheim Pharmaceuticals, Inc., Serial No. 86852106 (November 27, 2017) [not precedential] (Opinion by Judge Frances Wolfson).The Board ignored applicant's feeble double entendre argument, but it agreed with applicant that the USPTO's evidence failed to show that the term "breathless" merely describes the subject services. [read post]
26 Oct 2017, 11:07 am by Jennifer Jordan, JD, MSCC
Boehringer Ingelheim Pharmaceuticals, Inc., et al. was dismissed for lack of standing on October 10, 2017. [read post]
30 Dec 2016, 2:58 pm
Permission to appeal in patent cases - farewell to the Pozzoli approachGuest Kat Eibhlin Vardy recaps the case Teva UK Ltd v Boehringer Ingelheim Pharma GmbH & Co KG, [2016] EWCA Civ 1296. [read post]